Skip to main content

Table 4 Prognostic factors for over all survival and TTF

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

  Over all survival Time to treatment Failure
Stratification Hazard ratio p-value 95% C.I. Hazard ratio p-value 95% C.I.
Sex (male/female) 0.123 0.0128 0.024–0.640 0.225 0.0095 0.073–0.695
Age (69/<69) 0.634 0.6082 0.111–3.692 2.380 0.2269 0.583–9.713
ECOG PS (PS0/PS1/PS2) 0.016 0.0015 0.001–0.259 0.230 0.0007 0.001–0.152
Species of tumor (BDca/GBca) 0.095 0.0198 0.013–0.688 0.001 0.0411 0.0856–0.943
Disease status (locally advanced/postoperative recurrence) 0.121 0.0179 0.021–0.695 0.802 0.7388 0.001–0.152
Radiation (yes/no) 8.369 0.1491 0.467–150.112 0.603 0.4586 0.158–2.299
Previous chemotherapy (yes/no) 0.143 0.0255 0.016–1.241 0.495 0.4086 0.094–2.622
Initial CEA level (1 UL/<1 UL) 1.098 0.9053 0.234–5.160 2.453 0.1267 0.775–7.763
Interval decreasing CEA level (yes/no) 0.224 0.2859 0.014–3.499 1.734 0.5968 0.260–11.568
Initial CA19-9 level (5 UL/<5 UL) 0.078 0.0255 0.014–3.499 1.734 0.5968 0.260–11.568
Interval decreasing CA19-9 level(yes/no) 1.449 0.7667 0.125–16.774 0.326 0.2600 0.047–2.290
  1. (Cox proportional hazard model)
  2. Abbreveations
  3. BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status, CEA: carcinoembryonic antigen, UL: upper limit